Skip to content

How to Use Tesamorelin: Administration, Reconstitution & Storage (2026)

From Peptidepedia, the trusted peptide wiki.

How to Use / Administration

Tesamorelin administration occurs via subcutaneous injection, typically into abdominal areas with rotating injection sites to prevent lipohypertrophy.

Preparation: Wash hands thoroughly. Allow reconstituted solution to reach room temperature if refrigerated. Inspect solution for particulates or discoloration. It should remain clear and colorless.

Injection Technique: Clean injection site with alcohol swab. Pinch skin fold and insert needle at 45-90 degree angles depending on body composition. Inject slowly and steadily, then withdraw needle and apply gentle pressure without rubbing.

Timing Optimization: Administration timing influences efficacy. Morning injection on an empty stomach (at least 2 hours after eating and 30-60 minutes before food) takes advantage of naturally lower insulin levels, as insulin can blunt GH release. Alternatively, bedtime administration aligns with natural nocturnal GH surge. Avoid injection within 2-3 hours of consuming carbohydrates or fats, as elevated blood glucose and free fatty acids can inhibit GH secretion.

Reconstitution, Storage & Preparation

Tesamorelin typically arrives as lyophilized (freeze-dried) powder requiring reconstitution before use.

Reconstitution Process:

  1. Allow vial to reach room temperature
  2. Use bacteriostatic water (preferred for multi-dose vials) or sterile water
  3. Inject diluent slowly against vial wall, allowing it to run down the side rather than directly onto powder
  4. Gently swirl, never shake, until fully dissolved
  5. The resulting solution should remain clear and colorless

Concentration: Standard reconstitution uses 2 mL bacteriostatic water per 2 mg vial, yielding a 1 mg/mL concentration. This allows convenient dosing with standard insulin syringes.

Storage Guidelines:

  • Unreconstituted powder: Refrigerate at 2-8°C (36-46°F), protect from light
  • Reconstituted with bacteriostatic water: Refrigerate, use within 14-28 days
  • Reconstituted with sterile water: Refrigerate, use within shorter window
  • Never freeze reconstituted solution
  • Do not use if cloudy or contains particulates

Frequently Asked Questions

Most users begin noticing subtle improvements in body composition between weeks 8-12, with more significant visceral fat reduction becoming apparent by weeks 16-26. Clinical trials demonstrated statistically significant results at the 26-week mark.

Clinical trials have evaluated tesamorelin use for up to 52 weeks with maintained efficacy and acceptable safety profiles. However, long-term data beyond this period remains limited, and discontinuation typically results in gradual return of visceral fat accumulation.

Morning administration on an empty stomach or bedtime injection both represent common approaches. The key consideration involves avoiding injection within 2-3 hours of food intake, particularly carbohydrates, as elevated insulin and blood glucose can blunt GH release.

Tesamorelin remains contraindicated in patients with active malignancy due to theoretical concerns that elevated GH/IGF-1 could promote tumor growth. However, clinical trials have not demonstrated increased cancer incidence with tesamorelin use in appropriate patient populations.

Reconstituted tesamorelin requires refrigeration at 2-8°C (36-46°F) and light protection. When reconstituted with bacteriostatic water, it remains stable for approximately 14-28 days. Never freeze reconstituted solution.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370.
  2. Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat. Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291-4304.
  3. Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014;312(4):380-389.
  4. Makimura H, et al. Effects of tesamorelin on cardiometabolic risk factors in HIV-infected patients. Journal of Clinical Endocrinology & Metabolism. 2011;96(9):2831-2838.
  5. Fourman LT, et al. Tesamorelin treatment for liver fat and histology in HIV-associated NAFLD. Journal of Clinical Investigation. 2019;129(11):4608-4615.
  6. Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Archives of Neurology. 2012;69(11):1420-1429.
  7. Sevigny JJ, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008;71(21):1702-1708.
  8. Dhillon S. Tesamorelin: A Review of its Use in the Management of HIV-Associated Lipodystrophy. Drugs. 2011;71(8):1071-1091.
  9. FDA Prescribing Information for Egrifta SV (tesamorelin).
  10. World Anti-Doping Agency 2024 Prohibited List.
  11. Spooner LM, et al. Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy. Annals of Pharmacotherapy. 2012;46(2):240-247.
  12. Stanley TL, et al. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat. AIDS. 2011;25(10):1281-1288.

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”